Phase 3 international trial of adjuvant whole brain radiotherapy (WBRT) or observation (Obs) following local treatment of 1-3 melanoma brain metastases (MBMs).
Fogarty G. et al, (2019), JOURNAL OF CLINICAL ONCOLOGY, 37
Progression-free survival (PFS) in unresectable melanoma patients (pts) treated with talimogene laherparepvec (T-VEC) versus granulocyte macrophage colony-stimulating factor (GM-CSF) in OPTiM.
Milhem MM. et al, (2019), JOURNAL OF CLINICAL ONCOLOGY, 37
Quality of life (QoL) and symptom burden in patients (pts) with advanced melanoma during the treatment-free interval (TFI) after discontinuation of nivolumab (NIVO) or NIVO plus ipilimumab (IPI).
Taylor F. et al, (2019), JOURNAL OF CLINICAL ONCOLOGY, 37
Relationship between clinical efficacy and AEs of IMCgp100, a novel bispecific TCR-anti-CD3, in patients with advanced melanoma.
Middleton MR. et al, (2019), JOURNAL OF CLINICAL ONCOLOGY, 37
Resensitization of uveal melanoma (UM) to immune checkpoint inhibition (ICI) by IMCgp100 (IMC).
Yang J. et al, (2019), JOURNAL OF CLINICAL ONCOLOGY, 37
Immunotherapy-related hepatitis: real-world experience from a tertiary centre
CHEUNG VINCENT. et al, (2019), Frontline Gastroenterology
A phase Ib dose-finding, pharmacokinetic study of the focal adhesion kinase inhibitor GSK2256098 and trametinib in patients with advanced solid tumours.
Mak G. et al, (2019), Br J Cancer, 120, 975 - 981
Combining conventional therapy with immunotherapy: A risky business?
Coosemans A. et al, (2019), Eur J Cancer, 113, 41 - 44
Gene-expression profiling of bortezomib added to standard chemoimmunotherapy for diffuse large B-cell lymphoma (REMoDL-B): an open-label, randomised, phase 3 trial.
Davies A. et al, (2019), Lancet Oncol, 20, 649 - 662
Paper and electronic versions of HM-PRO, a novel patient-reported outcome measure for hematology: an equivalence study.
Goswami P. et al, (2019), J Comp Eff Res, 8, 523 - 533
Male gender is an independent predictor for worse survival and relapse in a large, consecutive cohort of elderly DLBCL patients treated with R-CHOP.
Eyre TA. et al, (2019), British journal of haematology
Quality assurance guidance for scoring and reporting for pathologists and laboratories undertaking clinical trial work.
Robinson M. et al, (2019), J Pathol Clin Res, 5, 91 - 99
Training and accreditation standards for pathologists undertaking clinical trial work.
Rees G. et al, (2019), J Pathol Clin Res, 5, 100 - 107
Correction to: Will the reformed Cancer Drugs Fund address the most common types of uncertainty? An analysis of NICE cancer drug appraisals.
Morrell L. et al, (2019), BMC health services research, 19, 198 - 198
Single-cell approaches reveal novel cellular pathways for megakaryocyte and erythroid differentiation.
Psaila B. and Mead AJ., (2019), Blood, 133, 1427 - 1435
Single-cell assessment of transcriptome alterations induced by Scriptaid in early differentiated human haematopoietic progenitors during ex vivo expansion
ROBERTS IRENE. et al, (2019), Scientific Reports
Immunotherapy-related hepatitis: Real-world experience from a tertiary centre
Cheung V. et al, (2019), Frontline Gastroenterology
Unravelling Intratumoral Heterogeneity through High-Sensitivity Single-Cell Mutational Analysis and Parallel RNA Sequencing.
Rodriguez-Meira A. et al, (2019), Mol Cell, 73, 1292 - 1305.e8
UK results from the myeloproliferative neoplasms (MPN) landmark survey on the symptom, emotional and economic burden of MPN.
Harrison C. et al, (2019), British journal of haematology
A phase I study to assess the safety and tolerability of intravesical pembrolizumab in recurrent non-muscle invasive bladder cancer (NMIBC).
Woodcock VK. et al, (2019), JOURNAL OF CLINICAL ONCOLOGY, 37